Dr. Yolanda Augustin is a Malaysian oncologist with a special interest in sarcoma and global oncology. She did her undergraduate, medical and palliative care training at Guy’s, King’s and St Thomas School of Medicine before undertaking clinical oncology training at the Royal Marsden, London. Upon completion of her oncology training, she undertook a research fellowship with the Royal Marsden Sarcoma Unit focused on clinical trial design and delivery of systemic anticancer therapies and radiotherapy trials. She is currently working on sarcoma service development, research and training in Malaysia including establishing a national prospective sarcoma database and sarcoma patient advocacy group.

She also co-leads a global oncology programme at St George’s, University of London focused on developing affordable therapeutics and diagnostics for cancer and infectious disease in Low and Middle Income Countries (LMICs). The programme brings together interdisciplinary experts from academia, global health and industry, with research collaborations in Malaysia, Vietnam, India and Senegal. Current projects include drug repurposing/repositioning for cancer, affordable point-of-care diagnostics for HPV DNA screening for cervical cancer and development pipelines for affordable cancer therapeutics. Her team also runs advocacy programmes with community health care champions and local stakeholders in rural communities in Sarawak, Malaysia aimed at removing barriers to equitable healthcare access and cancer service delivery.

Dr Robert James “RJ” Cusimano is a cardiac surgeon at the Peter Munk Cardiac Centre at the Toronto General Hospital and is a Professor of Surgery at the University of Toronto. He is the inaugural holder of the Cynamon Professorship in Cardiovascular Innovation and Education at the Peter Munk Cardiac Centre. In addition to his clinical duties, he has been deeply interested in education. He was the programme director of Cardiac surgery at the University of Toronto and at the Royal Collage of Physicians and Surgeons of Canada, helped in the development and implimentation of the Competency based curriculum now in existence in Canada. He has taught both within the University, Canada and internationally, having either taught or helped in programme development in China, Ethiopia, Sri Lanka, Brazil, Europe and the US. In 2016 he conceived and held the first Toronto Cardiac Tumour Conference, which brings the world’s experts in the field of cardiac tumours on a yearly basis. Recently, he conceived and has been working on the INTERACT project (INTernational Registry to Assess Cardiac Tumours), a global initiative to capture all cardiac tumours in the world. This is a multi-national, multidisciplinary endevour which will bring centres around the world together to try to improve care and outcome in these very rare tumours. Recently he was in Africa to help develop a plan to harmonize interaction on the continent. Eventually he would like to develop a subspecialty of cardiac surgery in the area of cardiac tumours.

Dr. Elizabeth Demicco is a Bone and Soft Tissue Pathologist and Section Head of Surgical Pathology at Mount Sinai Hospital in Toronto, and Associate Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. Dr. Demicco earned her MD and PhD in Biochemistry at Boston University School of Medicine and completed residency in Anatomic Pathology at the Massachusetts General Hospital, followed by fellowships in Selective Pathology (Soft Tissue and Cancer Biomarkers) at The University of Texas MD Anderson Cancer Center. She previously was on the faculty at Mount Sinai Hospital in New York where she served as the director of the Bone and Soft Tissue (2016-2017) and the Head and Neck Pathology Services (2014-2017). Dr. Demicco’s clinical and research focus is on the diagnosis and molecular biology of mesenchymal tumors. She has co-authored over 85 manuscripts and multiple book chapters in the field of bone and soft tissue pathology and was awarded the 2018 Junior Scientist Award from the Canadian Association of Pathology for her research contributions in the field. She is a past member of the board of directors of the Connective Tissue Oncology Society and has played active roles in international collaborative studies in the sarcoma field, including The Cancer Genome Atlas project, and the Clinical Proteomic Tumor Analysis Consortium.

Kristie Fernamberg joined Boehringer Ingelheim in 2013 and is currently Senior Global Medical Advisor for the MDM2-p53 antagonist program. She joined the global team in 2020 and previously worked on the KRAS programs. She has more than 15 years’ experience in the pharmaceutical industry with a strong scientific and clinical acumen in Oncology particularly in the field of Lung Cancer.

Paul Huang is Head of the Molecular and Systems Oncology Laboratory at The Institute of Cancer Research (ICR) in London, UK. He received his PhD in Biological Engineering from Massachusetts Institute of Technology in 2008 and is a Reader is Molecular & Translational Oncology at ICR. His laboratory focuses on understanding aberrant signalling networks and drug resistance in sarcomas, with the goal of developing biomarkers and new therapies for these rare diseases. Paul is the Deputy Director of the Joint Royal Marsden-ICR Sarcoma Research Centre. He serves as Vice Chair of the Pathology & Translational Research Committee of the EORTC Soft Tissue and Bone Sarcoma Group and was elected a Fellow of the Royal Society of Biology in 2020.

Professor Jones has both a private and an NHS practice at The Royal Marsden. He is a medical oncologist specialising in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden hospital in London England.

He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.

His main research interest focuses on clinical trials and translational research in sarcomas. He is a member of the Sarcoma Alliance for Research through Collaboration (SARC) concept review committee, European Organization for Research and Treatment of Cancer (EORTC) Sarcoma Group, the American Joint Committee on Cancer (AJCC) soft tissue sarcoma staging panel. He has previously served on the American Society of Clinical Oncology (ASCO) Educational Committee and the National Comprehensive Cancer Network (NCCN) Bone Tumour Panel.

Mehdi Lahmar joined Boehringer Ingelheim in Germany as a Clinical Program Lead in Oncology in November 2019 and is currently Evidence Lead for the MDM2-p53 antagonist program at BI. He was previously Head of Project Development in a Paris biotech company, Gamamabs, where he was responsible for advancing the company’s pipeline, coordinating the preclinical and clinical stage candidates in immune-oncology as well as interfacing with number of external stakeholders. He contributed to the advancement of drug candidates from Phase I to later stages of development. Prior to Gamamabs, Mehdi worked as project and team lead for number of drug development programs (monoclonal antibodies, small molecules and vaccines) in different therapeutic areas (infectious diseases, immunology and oncology) at Vivalis and Valneva; leading multinational teams across all functions. He received his PhD in Biotechnological Therapeutics from Paris Diderot (Paris7) University in 2008 and his Medical Degree (Obstetrics Gynaecology Oncology) from Tunis Medical School in 2003 and trained in number of French Hospitals among which the European Hospital George Pompidou (Department of oncological surgery) and Tenon Hospital in Paris (Department of obstetrics, gynaecology and oncology).

She graduated in 1993 and subsequently specialist in medical oncology. She is a world leader in sarcoma research and has been president of the Italian sarcoma group and has leading roles in the European society for medial oncology (ESMO and connective tissue oncology society (CTOS) and other societies. She is on the list of external experts of the European Medical Agency (EMA). She is a widely published and a very important oncologist sought out around the world.

Dr. Theuer has been CEO and President and a Director of TRACON Pharmaceuticals (NASDAQ: TCON) since 2006. Prior thereto, from October 2004 to July 2006, Dr. Theuer was Chief Medical Officer at TargeGen Inc., where he initiated the development of small molecule kinase inhibitors in oncology (including Inrebic® (fedratinib), a JAK2 inhibitor approved for myelofibrosis), ophthalmology and cardiovascular disease. From October 2003 to October 2004, Dr. Theuer was the Director, Clinical Oncology at Pfizer, where he led the clinical development of Sutent® (sunitinib) in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in January 2006 for treating advanced kidney cancer. Prior thereto, Dr. Theuer held senior positions at IDEC Pharmaceuticals, from June 2002 to October 2003, and the National Cancer Institute developing other agents, including small molecules and monoclonal antibody therapies. Dr. Theuer holds a B.S. degree from the Massachusetts Institute of Technology, an M.D. degree from the University of California, San Francisco and a Ph.D. degree from the University of California, Irvine. He completed a residency in general surgery at Harbor-UCLA Medical Center and was Board Certified in general surgery in 1997. Dr. Theuer held academic positions at the National Cancer Institute and at the University of California, Irvine, where he was a member of the Division of Surgical Oncology and Department of Medicine. His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, as well as gastro-intestinal cancer epidemiology. He serves as a Board member of TRACON Pharmaceuticals, 4D Molecular Therapeutics (NASDAQ: FDMT), and Oncternal Therapeutics (NASDAQ: ONCT).

Dr Ravi is a Professor, both in the Department of Sarcoma Medical Oncology and in the Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. After medical school, he earned a degree in Epidemiology and subsequently an MBA. He did his residency at Columbia University and fellowship in Medical Oncology at Roswell Park Cancer

Institute, which invited him on staff. Since 2008 he has been at the MD Anderson Cancer Center. He is the Research Director, The University of Texas Health Intelligence Platform, a Steering Committee Member, University of Texas System Clinical Data Network and the Clinical Medical Director, Translational Research Accelerator, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center.

Dr Albiruni Abdul Razak is an Associate Professor of Medicine at the University of Toronto. He is a clinician investigator based at Princess Margaret Cancer Centre and Mount Sinai Hospital. Originally from Malaysia, he obtained his medical degree in Ireland under a scholarship. After completing general medical residency, he completed oncology fellowships both in Ireland and England. Dr Abdul Razak then undertook a drug development fellowship at the Princess Margaret and transitioned into staff position in 2013, with a focus on sarcoma and early drug development. He is Medical Oncology Sarcoma Site Lead, Princess Margaret Cancer Centre and Mount Sinai Hospital, Clinician Investigator, Lunenfeld-Tanenbaum Research Institute and Chair, Sarcoma IND working group, Canadian Cancer Trials Group. He has been the principal investigator or co-investigator in more than 120 clinical trials and has published over 100 journal articles.

Michael Wagner, MD is an Associate Professor of Medicine and Director of Sarcoma Clinical Research at the University of Washington and an Associate Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, WA. After graduating from Harvard University with a medical degree, Dr. Wagner completed his residency at Mt. Sinai Hospital in New York and a medical oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Wagner has received numerous awards, including the Conquer Cancer Foundation of ASCO Young Investigator Award and QuadW Foundation-AACR Fellowship for Clinical/Translational Research for his research on sarcoma. His research interests include angiosarcoma and other vascular sarcomas, and bone and soft tissue sarcomas.

Dr. Geoffrey Watson is a Staff Medical Oncologist at Mount Sinai Hospital and an Assistant Professor of Medicine at the University of Toronto. He completed his basic and specialized training in medical oncology in Dublin, Ireland and has also received a Bachelor of Science degree in Computer Science as well as a Master’s degree in Pharmacological Bioinformatics at University College Dublin, Ireland.

Dr. Watson joined the Drug Development and Sarcoma Programs at the Princess Margaret Cancer Centre as a clinical research fellow in 2019. During this time he served as the Chief Fellow of the Division of Medical Oncology and Hematology, and was awarded with a Hold’em for Life Oncology Clinician Scientist Award in 2019, an ASCO Merit Award in 2020 and 2021 as well as the Novartis Oncology Young Canadian Investigator Award in 2020 and 2021.

Dr. Watson’s clinical focus is on the treatment of sarcoma and breast cancer. His academic interest is in patient reported outcomes and quality of life, and he also has an interest in teaching and education, particularly the evolving role of virtual education.

Sudha Yalamanchili is a Nurse Practitioner in Sarcoma Medical Oncology at MD Anderson Cancer Center. She works in a clinical practice with Dr. Ravi, which specializes in vascular tumors with particular focus on Angiosarcoma & Epithelioid Hemangioendothelioma. She serves as the APRN representative for the new patient team to help streamline incoming patients. She is involved with managing logistics for cardiac sarcoma patients to ensure delivery of multidisciplinary care and support services.